Education
About Us
Working with TipRanks
Follow Us
Cybin (CYBN)
:CYBN
CYBN Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CYBN Stock 12 Month Forecast
Average Price Target
$93.00
▲(1123.68% Upside)
| Highest Price Target$150.00 | Average Price Target$93.00 | Lowest Price Target$25.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Canaccord Genuity
$70
Buy
821.05%
Upside
Reiterated
08/14/25
Cybin's Promising Pipeline and Upcoming Milestones Justify Buy RatingWe recently hosted a fireside chat with CYBN's CEO Doug Drysdale at our 2025 Canaccord Genuity Growth Conference in Boston, MA. Recall CYBN's CYB003 (deuterated psilocin analog) is in a Phase 3 program (PARADIGM) for adjunctive treatment of major depressive disorder (MDD), and CYB004 (deuterated DMT) is in Phase 2 for generalized anxiety disorder (GAD). The key takeaways from our discussion were CYBN: 1) still expects to report top-line data from the first Phase 3 trial (APPROACH) for CYB003 in MDD in C2H26; 2) expects to report top-line data from the second Phase 3 trial (EMBRACE) in mid-C2027E and file a new drug application for CYB003 sometime before the end of C2027E; and 3) expects to complete dosing in its Phase 2 trial for CYB004 in GAD in August-25 with a potential data readout later in C2025E.
H.C. Wainwright
$150
Buy
1873.68%
Upside
Reiterated
07/03/25
Alliance Global Partners
$25
Buy
228.95%
Upside
Reiterated
07/02/25
Bloom Burton
$114
Buy
1400.00%
Upside
Reiterated
06/24/25
Lucid Capital
$106
Buy
1294.74%
Upside
Initiated
06/06/25
TR | OpenAI - 4o
―
Sell
―
Reiterated
04/24/25
Guggenheim
$35
Buy
360.53%
Upside
Initiated
03/12/25
Cybin wins new Buy from Guggenheim: potential to challenge JJs Spravato citedGuggenheim has initiated its coverage of psychedelic drug developer Cybin ( NYSE:CYBN ) with a Buy rating and a $35 per share target, indicating that the companys lead asset, CYB003, can one-day rival JJs (JNJ) FDA-approved depression therapy Spravato.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Canaccord Genuity
$70
Buy
821.05%
Upside
Reiterated
08/14/25
Cybin's Promising Pipeline and Upcoming Milestones Justify Buy RatingWe recently hosted a fireside chat with CYBN's CEO Doug Drysdale at our 2025 Canaccord Genuity Growth Conference in Boston, MA. Recall CYBN's CYB003 (deuterated psilocin analog) is in a Phase 3 program (PARADIGM) for adjunctive treatment of major depressive disorder (MDD), and CYB004 (deuterated DMT) is in Phase 2 for generalized anxiety disorder (GAD). The key takeaways from our discussion were CYBN: 1) still expects to report top-line data from the first Phase 3 trial (APPROACH) for CYB003 in MDD in C2H26; 2) expects to report top-line data from the second Phase 3 trial (EMBRACE) in mid-C2027E and file a new drug application for CYB003 sometime before the end of C2027E; and 3) expects to complete dosing in its Phase 2 trial for CYB004 in GAD in August-25 with a potential data readout later in C2025E.
H.C. Wainwright
$150
Buy
1873.68%
Upside
Reiterated
07/03/25
Alliance Global Partners
$25
Buy
228.95%
Upside
Reiterated
07/02/25
Bloom Burton
$114
Buy
1400.00%
Upside
Reiterated
06/24/25
Lucid Capital
$106
Buy
1294.74%
Upside
Initiated
06/06/25
TR | OpenAI - 4o
―
Sell
―
Reiterated
04/24/25
Guggenheim
$35
Buy
360.53%
Upside
Initiated
03/12/25
Cybin wins new Buy from Guggenheim: potential to challenge JJs Spravato citedGuggenheim has initiated its coverage of psychedelic drug developer Cybin ( NYSE:CYBN ) with a Buy rating and a $35 per share target, indicating that the companys lead asset, CYB003, can one-day rival JJs (JNJ) FDA-approved depression therapy Spravato.
Best Analysts Covering Cybin
1 Month
xxx
Success Rate
5/14 ratings generated profit
Average Return
-4.44%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 35.71% of your transactions generating a profit, with an average return of -4.44% per trade.
3 Months
xxx
Success Rate
7/14 ratings generated profit
Average Return
+2.60%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +2.60% per trade.
1 Year
Success Rate
3/21 ratings generated profit
Average Return
-25.04%
reiterated a buy rating last month
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -25.04% per trade.
2 Years
xxx
Success Rate
1/21 ratings generated profit
Average Return
-38.40%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 4.76% of your transactions generating a profit, with an average return of -38.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CYBN Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
6
5
2
3
6
Buy
0
0
0
0
0
Hold
1
1
1
0
0
Sell
2
3
2
2
0
Strong Sell
0
0
0
0
0
total
9
9
5
5
6
Each month's total comprises the sum of three months' worth of ratings.
CYBN Financial Forecast
CYBN Stock Forecast FAQ
What is CYBN’s average 12-month price target, according to analysts?
Based on analyst ratings, Cybin’s 12-month average price target is 93.00.
What is CYBN’s upside potential, based on the analysts’ average price target?
Cybin has 1123.68% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CYBN a Buy, Sell or Hold?
Cybin has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is Cybin’s price target?
The average price target for Cybin is 93.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $150.00 ,the lowest forecast is $25.00. The average price target represents 1123.68% Increase from the current price of $7.6.
The highest analyst price target is $150.00 ,the lowest forecast is $25.00. The average price target represents 1123.68% Increase from the current price of $7.6.
What do analysts say about Cybin?
Cybin’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of CYBN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.